November 12, 2016
Bristol-Myers Squibb Company has announced positive results from the Phase 1/2 open-label CheckMate-032 trial that investigates two combination schedules of Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with locally advanced or metastatic urothelial carcinoma (mUC) previously treated with platinum-based therapy. These data were presented during the Oral Late-breaking Abstract Session II, at the 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Md.
Urothelial carcinoma is the most common type of bladder cancer. It accounts for approximately 90% of bladder cancer cases. Bladder cancer is the ninth most commonly diagnosed cancer in the world, with more than 165,000 deaths annually, and an estimated 430,000 new cases diagnosed per year.
Padmanee Sharma, M.D., Ph.D., study investigator and professor at The University of Texas MD Anderson Cancer Center, said: “Metastatic urothelial carcinoma is an area of significant unmet medical need, especially for patients in the advanced stages of the disease who have progressed on standard chemotherapy. Earlier this year, we presented encouraging results from this trial for Opdivo monotherapy, and now we are seeing the promise of a combination regimen with Opdivo and Yervoy for previously treated patients with this common type of advanced bladder cancer. These findings support the need for further study of combination therapy to assess outcomes and potential survival in patients with metastatic urothelial carcinoma.”
“These results from the CheckMate -032 study support further development of the Opdivo plus Yervoy regimen for treatment of metastatic urothelial carcinoma in platinum refractory patients. The findings also bolster our belief that combining our Immuno-Oncology agents, Opdivo and Yervoy, can potentially advance cancer care,” commented Vicki Goodman, M.D., development lead, Melanoma and Genitourinary Cancers, Bristol-Myers Squibb.